Wave Life Sciences Ltd. – NASDAQ:WVE

Wave Life Sciences Ltd. stock price today

$9.52
-3.38
-26.2%
Financial Health
0
1
2
3
4
5
6
7
8
9

Wave Life Sciences Ltd. stock price monthly change

+129.54%
month

Wave Life Sciences Ltd. stock price quarterly change

+129.54%
quarter

Wave Life Sciences Ltd. stock price yearly change

+153.44%
year

Wave Life Sciences Ltd. key metrics

Market Cap
2.06B
Enterprise value
318.95M
P/E
-2.29
EV/Sales
55.23
EV/EBITDA
-1.16
Price/Sales
64.05
Price/Book
-8.20
PEG ratio
-0.17
EPS
-0.52
Revenue
112.91M
EBITDA
-70.06M
Income
-61.66M
Revenue Q/Q
-3.02%
Revenue Y/Y
661.49%
Profit margin
-4172.72%
Oper. margin
-4208.14%
Gross margin
6.49%
EBIT margin
-4208.14%
EBITDA margin
-62.05%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Wave Life Sciences Ltd. stock price history

Wave Life Sciences Ltd. stock forecast

Wave Life Sciences Ltd. financial statements

Average Price Target
Last Year

$20.75

Potential upside: 117.96%

Based on estimate of 7 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Wave Life Sciences Ltd. (NASDAQ:WVE): Profit margin
Jun 2023 22.10M -21.10M -95.47%
Sep 2023 49.21M 7.25M 14.74%
Dec 2023 29.05M -16.25M -55.95%
Mar 2024 12.53M -31.55M -251.7%
Wave Life Sciences Ltd. (NASDAQ:WVE): Earnings per share (EPS)
2024-03-06 -0.19 -0.15
2024-05-09 -0.18 -0.24
Wave Life Sciences Ltd. (NASDAQ:WVE): Debt to assets
Jun 2023 229985000 281.70M 122.49%
Sep 2023 199918000 240.40M 120.25%
Dec 2023 274949000 227.44M 82.72%
Mar 2024 235270000 202.00M 85.86%
Wave Life Sciences Ltd. (NASDAQ:WVE): Cash Flow
Jun 2023 -37.25M -72K 1.84M
Sep 2023 -34.45M -198K 1.67M
Dec 2023 -33.05M -354.39K 93.47M
Mar 2024 -33.43M -417K 14.51M

Wave Life Sciences Ltd. alternative data

Wave Life Sciences Ltd. (NASDAQ:WVE): Employee count
Aug 2023 250
Sep 2023 250
Oct 2023 250
Nov 2023 250
Dec 2023 250
Jan 2024 250
Feb 2024 250
Mar 2024 266
Apr 2024 266
May 2024 266
Jun 2024 266
Jul 2024 266

Wave Life Sciences Ltd. other data

19.54% -53.02%
of WVE is owned by hedge funds
15.40M -52.72M
shares is hold by hedge funds

Wave Life Sciences Ltd. (NASDAQ:WVE): Insider trades (number of shares)
Period Buy Sel
Dec 2023 2000000 0
Apr 2024 0 15630
Aug 2024 0 48366
Sep 2024 2791930 17146
Oct 2024 0 299310
Nov 2024 0 137234
Transaction Date Insider Security Shares Price per share Total value Source
Option
BOLNO PAUL director, officer: President an..
Ordinary Shares 50,000 $2.48 $124,000
Sale
BOLNO PAUL director, officer: President an..
Ordinary Shares 50,000 $15 $750,000
Option
BOLNO PAUL director, officer: President an..
Share Option (right to buy) 50,000 $2.48 $124,000
Sale
BOLNO PAUL director, officer: President an..
Ordinary Shares 51,234 $14.32 $733,671
Option
FRANCIS CHRIS officer: See Remarks
Ordinary Shares 36,000 $8.17 $294,120
Sale
FRANCIS CHRIS officer: See Remarks
Ordinary Shares 36,000 $16 $576,000
Option
FRANCIS CHRIS officer: See Remarks
Share Option (right to buy) 36,000 $8.17 $294,120
Option
FRANCIS CHRIS officer: See Remarks
Share Option (right to buy) 65,625 $3.14 $206,063
Option
FRANCIS CHRIS officer: See Remarks
Ordinary Shares 65,625 $3.14 $206,063
Option
FRANCIS CHRIS officer: See Remarks
Ordinary Shares 40,997 $2.48 $101,673
Patent
Grant
Filling date: 13 Mar 2017 Issue date: 9 Aug 2022
Application
Filling date: 14 Jul 2021 Issue date: 23 Jun 2022
Application
Filling date: 6 Dec 2019 Issue date: 16 Jun 2022
Application
Filling date: 7 May 2020 Issue date: 26 May 2022
Application
Filling date: 8 May 2020 Issue date: 12 May 2022
Application
Filling date: 2 Sep 2021 Issue date: 28 Apr 2022
Application
Filling date: 30 Jan 2020 Issue date: 31 Mar 2022
Grant
Filling date: 19 May 2020 Issue date: 5 Oct 2021
Application
Filling date: 10 May 2019 Issue date: 19 Aug 2021
Application
Filling date: 12 Oct 2018 Issue date: 29 Jul 2021
Insider Compensation
Dr. Paul B. Bolno M.B.A., M.D., MBA (1974) Pres, Chief Executive Officer & Director
$961,470
Dr. Michael A. Panzara M.D., M.P.H., MPH (1967) Chief Medical Officer and Head of Therapeutics Discovery & Devel. $655,000
Dr. Chandra Vargeese Ph.D. (1961) Chief Technology Officer $619,200
Monday, 23 December 2024
globenewswire.com
Monday, 16 December 2024
globenewswire.com
Friday, 15 November 2024
globenewswire.com
Tuesday, 12 November 2024
seekingalpha.com
zacks.com
Tuesday, 5 November 2024
zacks.com
Wednesday, 30 October 2024
globenewswire.com
Monday, 28 October 2024
zacks.com
Thursday, 24 October 2024
fool.com
Wednesday, 23 October 2024
zacks.com
Monday, 21 October 2024
investors.com
Friday, 18 October 2024
marketbeat.com
Thursday, 17 October 2024
zacks.com
zacks.com
Wednesday, 16 October 2024
seekingalpha.com
benzinga.com
investors.com
globenewswire.com
Friday, 11 October 2024
zacks.com
Sunday, 6 October 2024
247wallst.com
Thursday, 3 October 2024
fool.com
Tuesday, 1 October 2024
globenewswire.com
Monday, 30 September 2024
globenewswire.com
Thursday, 26 September 2024
benzinga.com
Wednesday, 25 September 2024
globenewswire.com
zacks.com
Tuesday, 24 September 2024
globenewswire.com
marketwatch.com
globenewswire.com
Friday, 20 September 2024
marketbeat.com
  • What's the price of Wave Life Sciences Ltd. stock today?

    One share of Wave Life Sciences Ltd. stock can currently be purchased for approximately $9.52.

  • When is Wave Life Sciences Ltd.'s next earnings date?

    Unfortunately, Wave Life Sciences Ltd.'s (WVE) next earnings date is currently unknown.

  • Does Wave Life Sciences Ltd. pay dividends?

    No, Wave Life Sciences Ltd. does not pay dividends.

  • How much money does Wave Life Sciences Ltd. make?

    Wave Life Sciences Ltd. has a market capitalization of 2.06B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3005.1% to 113.31M US dollars. Wave Life Sciences Ltd. made a loss 57.51M US dollars in net income (profit) last year or -$0.24 on an earnings per share basis.

  • What is Wave Life Sciences Ltd.'s stock symbol?

    Wave Life Sciences Ltd. is traded on the NASDAQ under the ticker symbol "WVE".

  • What is Wave Life Sciences Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Wave Life Sciences Ltd.?

    Shares of Wave Life Sciences Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Wave Life Sciences Ltd.'s key executives?

    Wave Life Sciences Ltd.'s management team includes the following people:

    • Dr. Paul B. Bolno M.B.A., M.D., MBA Pres, Chief Executive Officer & Director(age: 51, pay: $961,470)
    • Dr. Michael A. Panzara M.D., M.P.H., MPH Chief Medical Officer and Head of Therapeutics Discovery & Devel.(age: 58, pay: $655,000)
    • Dr. Chandra Vargeese Ph.D. Chief Technology Officer(age: 64, pay: $619,200)
  • How many employees does Wave Life Sciences Ltd. have?

    As Jul 2024, Wave Life Sciences Ltd. employs 266 workers.

  • When Wave Life Sciences Ltd. went public?

    Wave Life Sciences Ltd. is publicly traded company for more then 9 years since IPO on 11 Nov 2015.

  • What is Wave Life Sciences Ltd.'s official website?

    The official website for Wave Life Sciences Ltd. is wavelifesciences.com.

  • How can i contact Wave Life Sciences Ltd.?

    Wave Life Sciences Ltd. can be reached via phone at +65 6236 3388.

  • What is Wave Life Sciences Ltd. stock forecast & price target?

    Based on 7 Wall Street analysts` predicted price targets for Wave Life Sciences Ltd. in the last 12 months, the avarage price target is $20.75. The average price target represents a 117.96% change from the last price of $9.52.

Wave Life Sciences Ltd. company profile:

Wave Life Sciences Ltd.

wavelifesciences.com
Exchange:

NASDAQ

Full time employees:

266

Industry:

Biotechnology

Sector:

Healthcare

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Marina One East Tower
Singapore, 018936

CIK: 0001631574
ISIN: SG9999014716
CUSIP: Y95308105